TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial

By Cynthia Umukoro

Share:

Featured:

Andreas BurchertAndreas Burchert

Dec 7, 2018


At the 60th American Society of Hematology (ASH) Annual Meeting, Andreas Burchert from the University of Marburg, Germany, discusses the study findings of the Sormain trial, which is evaluating sorafenib as maintenance therapy after allogeneic stem cell transplantation for patients with FLT3-ITD–positive acute myeloid leukemia.

English

German

Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial